ARLINGTON, Va., September 4, 2025 — As researchers and clinicians from across the globe prepare to gather at the Moscone Convention Center in San Francisco this month for the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, ASTRO announced today the studies selected for the meeting’s official press program. Researchers will discuss their findings in news briefings on September 29 and 30; meeting registration for credentialed press is available in the Annual Meeting press kit.
The field's most influential scientific forum, ASTRO’s 2025 Annual Meeting will feature pivotal studies in radiation medicine for patients with cancer and other diseases, with speakers and sessions spotlighting next-generation approaches that are making treatments safer, more effective and more personalized. Press program studies will highlight advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy, as well as first reports from clinical trials of cutting-edge techniques for prostate, breast, lung and other common cancers.
The news briefing schedule is as follows:
Monday, September 29, 11:00 a.m. Pacific time (2:00 p.m. Eastern)
-
A double-blinded placebo-controlled biomarker stratified randomized trial of apalutamide (APA) and radiotherapy for recurrent prostate cancer (NRG GU006, BALANCE trial) (LBA 04), presented by Daniel Spratt, MD
-
Clinical effectiveness of single course low-dose radiation therapy in knee osteoarthritis: Short-term results from the randomized, sham-controlled trial (LBA 06), presented by Byoung Hyuck Kim, MD, PhD
-
Bladder Adjuvant RadioTherapy (BART): Clinical outcomes from a phase III multicenter randomized controlled trial (Abstract 2), presented by Vedang Murthy, MD
-
177Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer: Primary endpoint analysis of the phase II LUNAR randomized trial (Abstract 3), presented by Amar Kishan, MD, PhD
-
Stereotactic arrhythmia radiotherapy (STAR) vs. repeat catheter ablation for high-risk refractory ventricular tachycardia: 3-year safety and efficacy outcomes (Abstract 247), presented by Shannon Jiang, MD
-
Moderated by Catheryn Yashar, MD, FASTRO, incoming ASTRO President-elect
Tuesday, September 30, 8:00 a.m. Pacific time (11:00 a.m. Eastern)
-
Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RADCOMP) consortium trial: Health-related quality of life outcomes (LBA 01), presented by Shannon MacDonald, MD, FASTRO
-
Primary results for the phase III trial of toxicity reduction using proton beam therapy for oropharyngeal cancer (TORPEdO; CRUK/18/010) (LBA 02), presented by David Thomson, MD
-
Primary results from NRG-GU005: A phase III trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer (Abstract 1), presented by Rodney Ellis, MD
-
Ten-year outcomes of the revised STARS trial comparing radiation and surgery for early-stage non-small cell lung cancer (Abstract 268), presented by Joe Chang, MD, PhD, FASTRO
-
Moderated by Kenneth Rosenzweig, MD, FASTRO, Chair of the ASTRO Annual Meeting Scientific Committee
Led by ASTRO President Sameer Keole, MD, FASTRO, the ASTRO’s 2025 Annual Meeting is expected to attract 10,000 oncologists, clinicians, researchers and other health care professionals from around the globe. The meeting’s theme, “Rediscovering Radiation Medicine and Exploring New Indications,” reflects the expanding uses of radiation therapy for non-cancerous indications. Dr. Keole's Presidential Symposium will feature multidisciplinary subject matter experts discussing radiation treatments for musculoskeletal (e.g., plantar fasciitis, osteoarthritis), cardiac (e.g., arrhythmias, early heart failure) and functional neurologic (e.g., tremors from Parkinson’s disease) conditions.
The meeting, which will take place September 27 to October 1, will feature more than 2,500 abstract presentations, educational expert panels on topics such as advances in radiopharmaceutical therapy and keynote addresses from Bobby Mukkamala, MD, president of the American Medical Association who had a grade 2 brain tumor removed in December 2024, and Bryant Lin, MD, MEng, a Stanford Medicine professor who is living with stage 4 lung cancer.
Schedule and presenter information is available in the Annual Meeting portal, and more information about the meeting can be found on ASTRO’s Annual Meeting website.
ABOUT ASTRO
The American Society for Radiation Oncology (ASTRO) is the world’s largest professional society dedicated to advancing radiation oncology, with 10,000 members including physicians, nurses, physicists, radiation therapists, dosimetrists and other professionals who work to improve patient outcomes through clinical care, research, education and policy advocacy. Radiation therapy is integral to 40% of cancer cures worldwide, and more than one million Americans receive radiation treatments for their cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and connect with us on social media.